{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:30:31Z","timestamp":1785886231554,"version":"3.56.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of a step-down treatment approach using mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) in a real-life single-centre cohort. The study aimed to assess outcomes following a transition from high-dose (300\u2009mg\/4\u2009weeks) to low-dose (100\u2009mg\/4\u2009weeks) mepolizumab after achieving remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included EGPA patients treated with mepolizumab between April 2014 and December 2024. Patients receiving step-down therapy were in remission, defined by a Birmingham Vasculitis Activity Score (BVAS) of 0, Asthma Control Test (ACT) &amp;gt;20 and steroid-free for at least one year. Disease activity, eosinophil counts and systemic glucocorticoids (GC) use were tracked in medical charts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 45 patients initially treated with 300\u2009mg\/4\u2009weeks, 12 (27%) switched to 100\u2009mg\/4\u2009weeks after a median of 26.5\u2009months. Over a median follow-up of 27.5\u2009months post-step-down, 50% maintained complete remission without GC therapy. In 50% of patients sinonasal symptoms recurred and were treated with either increased mepolizumab dose or optimization of local therapy. No asthma or vasculitis exacerbations occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our preliminary data show that step-down therapy with mepolizumab to 100\u2009mg\/4\u2009weeks was effective in maintaining systemic remission and reducing GC use in EGPA patients. However, recurrence of sinonasal symptoms suggests the need for an individualized management. Larger studies are warranted to confirm these findings and optimize dosing strategies for long-term care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf201","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:36:11Z","timestamp":1744356971000},"page":"5108-5111","source":"Crossref","is-referenced-by-count":10,"title":["Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-9106","authenticated-orcid":false,"given":"Luca","family":"Moroni","sequence":"first","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Batani","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, Milan,","place":["Italy"]},{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia , Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-5966","authenticated-orcid":false,"given":"Gabriele D","family":"Gallina","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Benanti","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cilona","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Cariddi","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4522-2921","authenticated-orcid":false,"given":"Marco","family":"Lanzillotta","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Dan\u00e8","sequence":"additional","affiliation":[{"name":"Unit of Otorhinolaryngology, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Tanzini","sequence":"additional","affiliation":[{"name":"Unit of Otorhinolaryngology, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan,","place":["Italy"]},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"2025090315112062600_keaf201-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025090315112062600_keaf201-B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ijms25105278","article-title":"Pathogenesis of pulmonary manifestations in ANCA-associated vasculitis and goodpasture syndrome","volume":"25","author":"Fouka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025090315112062600_keaf201-B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2024.06.008","article-title":"Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA)","author":"Solans Laqu\u00e9","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025090315112062600_keaf201-B4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/cup.14065","article-title":"Eosinophilic granulomatosis with polyangiitis: cutaneous clinical and histopathologic differential diagnosis","volume":"48","author":"Tabb","year":"2021","journal-title":"J Cutan Pathol"},{"key":"2025090315112062600_keaf201-B5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025090315112062600_keaf201-B6","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090315112062600_keaf201-B7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2024.08.009","article-title":"Unmasking eosinophilic granulomatosis with polyangiitis (EGPA)","volume":"128","author":"Moroni","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025090315112062600_keaf201-B8","doi-asserted-by":"crossref","first-page":"103219","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025090315112062600_keaf201-B9","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090315112062600_keaf201-B10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1361.053","article-title":"Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome","volume":"1051","author":"Hellmich","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2025090315112062600_keaf201-B11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"2025090315112062600_keaf201-B12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European Multicenter Observational Study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2025090315112062600_keaf201-B13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4168\/aair.2020.12.5.885","article-title":"Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Vultaggio","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"2025090315112062600_keaf201-B14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/02770903.2020.1827417","article-title":"Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?","volume":"58","author":"Vergles","year":"2021","journal-title":"J Asthma"},{"key":"2025090315112062600_keaf201-B15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir Res"},{"key":"2025090315112062600_keaf201-B16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roab005","article-title":"Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis","volume":"32","author":"Nakamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2025090315112062600_keaf201-B17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090315112062600_keaf201-B18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2025090315112062600_keaf201-B19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090315112062600_keaf201-B20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clicom.2022.01.002","article-title":"Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"2","author":"Ramirez","year":"2022","journal-title":"Clin Immunol Commun"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf201\/62923053\/keaf201.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5108\/62923053\/keaf201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5108\/62923053\/keaf201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:11:31Z","timestamp":1756926691000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/5108\/8112922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,4,12]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf201","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,12]]}}}